These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25436261)

  • 1. Basophilic blast phase of chronic myelogenous leukemia.
    Babiker HM; Proytcheva M
    Blood; 2014 Oct; 124(15):2464. PubMed ID: 25436261
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
    Vigil CE; Wang SA; Cortes JE; Bueso-Ramos C; Verstovsek S; Shinder R; Chen SS; Katz RL; Khanna A; Esmaeli B; Manning JT; You MJ; Miranda RN
    J Clin Oncol; 2011 Jun; 29(17):e514-6. PubMed ID: 21464405
    [No Abstract]   [Full Text] [Related]  

  • 3. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
    Nishimoto M; Nakamae H; Koh KR; Kosaka S; Matsumoto K; Morita K; Koh H; Nakane T; Ohsawa M; Hino M
    Acta Haematol; 2013; 130(2):111-4. PubMed ID: 23548721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
    Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
    Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
    [No Abstract]   [Full Text] [Related]  

  • 5. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
    Raanani P
    Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 10. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 12. Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.
    Angelopoulou MK; Asimakopoulos JV; Galani Z; Levidou G; Roumelioti M; Vassilakopoulos TP; Korkolopoulou P; Panayiotidis P
    Blood Cancer J; 2016 Aug; 6(8):e461. PubMed ID: 27564459
    [No Abstract]   [Full Text] [Related]  

  • 13. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basophilic leukemia in recurrent chronic myelogenous leukemia blast phase.
    Gill RM; Etzell JE
    Am J Hematol; 2007 Aug; 82(8):736-7. PubMed ID: 17492647
    [No Abstract]   [Full Text] [Related]  

  • 15. [Blast crisis of chronic myelogenous leukemia with blasts expressing both immature B lymphocyte- and myelomonocyte-associated antigens and differentiating into basophils in vitro].
    Utsunomiya Y; Iwamasa K; Yasukawa M; Tamai T; Shiosaka T; Bando S
    Rinsho Ketsueki; 1990 Jul; 31(7):1017-21. PubMed ID: 2214182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basophilic crisis in chronic myelogenous leukemia: case report and literature review in Japan.
    Yamauchi K; Arimori S
    Jpn J Med; 1990; 29(3):334-40. PubMed ID: 2273616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dasatinib monotherapy for intramedullary T-lymphocyte blast crisis in chronic myeloid leukemia: a case report].
    Zhang Y; Yang JB; Ma YM
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):608-609. PubMed ID: 39134498
    [No Abstract]   [Full Text] [Related]  

  • 18. Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib.
    Eckardt MA; Chang VY; Rao NP; Federman N
    Pediatr Hematol Oncol; 2011 Nov; 28(8):669-75. PubMed ID: 22023462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.